Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients

NCT04181203 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT04181203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04181203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 9, 2020
Completion date
December 28, 2033
Enrollment
490 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer